hematologic disease: A disease involving the hematopoietic system.
Other specified diseases with participation of lymphoreticular and reticulohistiocytic tissue
DOID EFO Endpoint Browser PheWeb
D3_OTHDISLYMPHORETANDRETICULOHIST
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
125 |
4. Check minimum number of eventsNone |
125 |
5. Include endpoints |
125 |
6. Filter based on genotype QC (FinnGen only) |
120 |
Control definitions (FinnGen only)
- Control exclude
- D3_BLOODOTHER
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- D70-D77
- Name in latin
- Aliqui morbi textus lymphoreticularis et systematis reticulohistiocytici
Similar endpoints
↥List of similar endpoints to
Other specified diseases with participation of lymphoreticular and reticulohistiocytic tissue
based on the number of shared cases.
Similar with more cases:
- Other diseases of blood and blood-forming organs, wide
- Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 896 | 420 | 473 |
| Only index persons | 719 | 332 | 387 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 34.32 | 35.37 | 33.34 |
| Only index persons | 41.02 | 42.89 | 39.42 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 120 | 57 | 63 |
| Unadjusted period prevalence (%) | 0.02 | 0.02 | 0.03 |
| Median age at first event (years) | 52.11 | 52.89 | 51.41 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 125
- Matched controls
- 1250
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D76.1
ICD-10 Finland
Haemophagocytic lymphohistiocytosis
+∞
55.4
49
*
D76.3
ICD-10 Finland
Other histiocytosis syndromes
+∞
52.9
47
*
D76.00
ICD-10 Finland
Eosinophilic granuloma
+∞
36.2
33
*
A49.9
ICD-10 Finland
Bacterial infection, unspecified
10.0
30.1
42
60
XW000
NOMESCO Finland
Bone marrow biopsy
39.8
28.2
35
12
D76.01
ICD-10 Finland
Histiocytosis X (chronic)
+∞
27.1
25
*
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
29.3
24.6
33
15
JN4AD
NOMESCO Finland
Body CT examination
8.4
21.2
32
49
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
10.2
20.0
25
30
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
6.4
19.4
41
89
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
5.7
19.1
49
127
UGC12
NOMESCO Finland
Flexible bronchoscopy
8.9
18.6
26
36
H02AB09
ATC
hydrocortisone; systemic
22.5
16.8
24
13
R50.9
ICD-10 Finland
Fever, unspecified
5.2
16.6
45
121
JN4BD
NOMESCO Finland
Extensive body CT
6.4
16.0
31
61
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
6.3
15.7
31
62
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
6.3
15.2
30
60
H02AB06
ATC
prednisolone; systemic
4.4
14.4
84
395
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
7.4
14.3
23
37
TNE25
NOMESCO Finland
Drill biopsy of bone marrow, pelvis
60.6
14.2
16
*
WW500
NOMESCO Finland
Blood transfusion
14.6
13.2
22
18
GD1AA
NOMESCO Finland
Thorax X-ray examination
4.0
12.7
80
387
H02AB02
ATC
dexamethasone; systemic
5.2
12.7
31
75
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
7.0
12.6
21
35
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
6.8
12.2
21
36
N17.9
ICD-10 Finland
Acute renal failure, unspecified
13.0
11.5
20
18
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
13.0
11.5
20
18
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
5.0
11.3
28
68
A41.9
ICD-10 Finland
Sepsis, unspecified
12.3
11.3
20
19
D76.0
ICD-10 Finland
Langerhans' cell histiocytosis, not elsewhere classified
+∞
10.6
10
*
D76.2
ICD-10 Finland
Haemophagocytic syndrome, infection-associated
+∞
10.6
10
*
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
5.2
10.3
24
55
GD1AD
NOMESCO Finland
Thorax CT examination
9.7
10.0
20
24
A04AA01
ATC
ondansetron; systemic, rectal
5.5
10.0
21
44
ZX120
NOMESCO Finland
Intravenous
5.0
9.9
24
57
D64.9
ICD-10 Finland
Anaemia, unspecified
4.8
9.5
24
59
D69.6
ICD-10 Finland
Thrombocytopenia, unspecified
20.5
9.1
13
7
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
3.9
9.0
32
102
JN6AD
NOMESCO Finland
CT of torso and neck
53.9
8.8
10
*
D70.82
ICD-10 Finland
Drug-induced neutropenia
+∞
8.4
8
*
TPH20
NOMESCO Finland
Insertion of central venous catheter through subclavian or brachiocephalic vein
14.3
8.1
13
10
R59.0
ICD-10 Finland
Localized enlarged lymph nodes
9.9
7.8
15
17
M04AA01
ATC
allopurinol; systemic
3.8
7.8
27
84
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
11.1
7.8
14
14
PJ2AE
NOMESCO Finland
Lymphnode ultrasound examination
84.9
7.5
8
*
JN6BD
NOMESCO Finland
Extensive CT of torso and neck
84.9
7.5
8
*
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.9
7.4
52
248
TPH04
NOMESCO Finland
Cathetrisation of vein
3.2
7.4
37
146
EN1AD
NOMESCO Finland
CT examination of mouth and soft tissues of neck
+∞
7.4
7
*
TPX10
NOMESCO Finland
Implantation of vascular injection port
8.4
7.1
15
20
EP1AE
NOMESCO Finland
Neck ultrasound examination
6.4
7.1
18
32
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
6.4
6.7
17
30
TPH90
NOMESCO Finland
Removal of fixed intravenous catheter
13.2
6.7
11
9
GD1ED
NOMESCO Finland
Extensive high resolution CT examination of lungs
8.1
6.6
14
19
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
7.3
6.6
15
23
WX002
NOMESCO Finland
Sedation and analgesia
3.1
6.5
32
124
TAB00
NOMESCO Finland
Lumbar puncture
5.7
6.5
18
36
JN4JR
NOMESCO Finland
Whole body extensive metabolic PET with CT
19.2
6.4
9
5
H02AB07
ATC
prednisone; oral
3.7
6.4
22
68
J01MA14
ATC
moxifloxacin; systemic
4.2
6.3
18
48
102
Kela drug reimbursment
Diabetes insipidus
+∞
6.3
6
*
JN6DR
NOMESCO Finland
PET-CT of whole body metabolism
+∞
6.3
6
*
L03AA02
ATC
filgrastim; parenteral
9.3
6.2
12
14
R70.0
ICD-10 Finland
Elevated erythrocyte sedimentation rate
13.4
6.2
10
8
WX892
NOMESCO Finland
Monitored bed care
4.2
6.0
17
45
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
4.0
6.0
18
50
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
42
38
16.14
42.09
3.2
1.9
1.52
1.67
g/l
0.29
32
31
43
7
92.30
40.25
8.2
1.7
3955.49
614.86
u/ml
—
43
7
32
28
15.02
32.24
2.5
2.7
—
—
—
0
0
56
139
6.49
23.51
12.3
8.2
1.13
1.17
mmol/l
0.33
56
127
27
10
33.97
21.10
3.8
4.5
—
—
—
0
0
31
20
20.17
20.62
2.3
3.1
—
—
—
0
0
23
7
39.76
18.73
2.1
1.4
—
—
—
0
0
56
168
5.23
18.35
12.3
5.8
0.80
0.81
mmol/l
0.18
56
156
27
42
7.92
17.45
8.9
3.8
93.19
92.74
%
0.03
27
42
16
0
+∞
17.06
2.2
0.0
—
—
—
0
0
28
25
14.08
16.29
3.7
1.9
—
—
—
0
0
51
157
4.80
15.88
7.3
2.5
29.44
30.11
s
0.35
51
152
27
24
14.01
15.72
3.1
1.9
—
—
—
0
0
96
483
5.26
15.42
20.3
7.8
1.21
1.22
mmol/l
0.10
77
417
24
17
17.15
15.30
1.5
1.6
—
—
—
0
0
26
23
13.95
15.16
1.5
1.5
—
—
—
0
0
25
21
14.57
14.89
1.4
1.9
—
—
—
0
0
25
22
13.89
14.60
1.6
2.3
—
—
—
0
0
23
20
13.81
13.48
4.0
1.8
—
—
—
0
0
30
67
5.58
13.45
1.4
1.3
77.10
172.88
u/ml
1.85
24
60
28
59
5.83
13.36
3.2
1.4
—
—
—
0
0
21
16
15.50
13.00
1.5
1.4
—
—
—
0
0
23
23
11.98
12.65
1.8
1.5
—
—
—
0
0
21
18
13.76
12.38
1.5
1.4
—
—
—
0
0
45
149
4.16
12.35
4.1
1.6
—
—
—
0
0
35
99
4.52
11.78
3.0
2.4
311.97
342.21
nmol/l
0.47
35
89
23
27
10.18
11.66
2.3
1.1
—
—
—
0
0
19
15
14.70
11.59
2.2
1.7
—
—
—
0
0
103
615
4.83
11.56
36.3
9.8
3.86
3.97
e9/l
0.17
95
531
21
22
11.23
11.29
1.6
2.3
284.45
132.55
u/ml
1.02
11
11
22
31
8.37
10.05
1.8
1.5
—
—
—
0
0
17
15
12.91
9.91
4.2
1.7
—
—
—
0
0
21
29
8.47
9.71
2.6
1.6
—
—
—
0
0
16
13
13.91
9.67
2.3
1.8
—
—
—
0
0
17
17
11.37
9.37
3.8
2.2
—
—
—
0
0
17
17
11.37
9.37
3.8
2.2
—
—
—
0
0
15
13
12.92
8.84
4.7
1.8
—
—
—
0
0
16
16
11.28
8.83
1.5
1.1
—
—
—
0
0
32
106
3.71
8.49
3.1
1.6
—
—
—
0
0
13
10
14.33
8.08
4.7
1.3
32.31
31.50
pg
—
13
10
17
23
8.37
7.99
2.1
1.2
—
—
—
0
0
12
8
16.41
7.89
1.7
1.3
—
—
—
0
0
30
101
3.59
7.72
3.2
1.5
—
—
—
0
0
77
450
2.85
7.46
7.2
2.7
—
—
—
0
0
11
7
17.04
7.37
1.8
1.1
—
—
—
0
0
10
5
21.55
7.26
2.9
1.4
—
—
—
0
0
18
32
6.39
7.09
10.4
3.3
202.06
206.66
%
0.07
18
32
11
8
14.91
7.03
1.2
1.0
—
—
—
0
0
11
8
14.91
7.03
1.2
1.0
—
—
—
0
0
73
431
2.67
6.69
15.6
12.9
1.13
1.24
inr
0.93
29
109
30
112
3.21
6.50
18.2
7.4
104.33
104.13
mmol/l
0.09
30
112
12
13
10.07
6.45
2.4
2.1
—
—
—
0
0
12
13
10.07
6.45
2.4
2.1
—
—
—
0
0
18
50
4.04
6.01
6.8
14.3
95.22
93.98
%
0.58
18
50
9
6
16.02
6.00
1.7
1.0
—
—
—
0
0
11
12
9.92
5.92
1.7
2.1
—
—
—
0
0
11
12
9.92
5.92
1.8
1.8
—
—
—
0
0
9
7
13.72
5.67
1.7
1.0
—
—
—
0
0
46
234
2.53
5.52
7.9
2.4
—
—
—
0
0
8
5
16.94
5.48
3.5
2.8
—
—
—
0
0
14
26
5.92
5.41
5.1
4.0
4.75
4.84
kpa
0.17
14
26
12
18
7.25
5.40
1.3
1.3
—
—
—
0
0
62
366
2.38
5.33
5.3
3.5
—
—
—
0
0
24
88
3.14
5.31
5.3
5.2
1.38
1.27
mmol/l
0.04
19
64
5
0
+∞
5.24
1.6
0.0
—
—
—
0
0
27
107
2.94
5.23
19.7
6.0
1.18
1.62
mmol/l
0.32
22
82
9
9
10.66
5.11
5.0
1.9
—
—
—
0
0
9
9
10.66
5.11
5.0
1.9
—
—
—
0
0
9
9
10.66
5.11
5.0
1.9
—
—
—
0
0
56
321
2.35
5.09
4.0
3.5
2.30
2.37
mmol/l
2.18
56
281
11
16
7.42
5.07
1.2
1.1
—
—
—
0
0
26
103
2.92
5.03
6.1
13.7
0.46
1.30
mmol/l
0.64
21
86
11
17
6.98
4.89
6.7
4.0
53.00
60.76
%
0.69
11
17
25
99
2.91
4.83
6.3
14.1
4.61
5.15
kpa
2.23
25
92
25
99
2.91
4.83
6.3
14.1
11.40
12.23
kpa
0.44
25
93
23
88
2.98
4.72
18.4
8.5
23.99
24.49
mmol/l
0.33
23
88
7
5
14.71
4.63
1.3
1.8
—
—
—
0
0
7
5
14.71
4.63
1.4
1.2
—
—
—
0
0
13
28
5.06
4.52
1.4
1.4
—
—
—
0
0
14
41
3.72
4.33
1.8
2.4
18.25
22.92
iu/l
—
8
33
9
13
7.36
4.24
1.4
1.2
—
—
—
0
0
9
13
7.36
4.24
1.4
1.1
1.80
1.34
g/l
—
9
13
13
31
4.56
4.15
1.2
1.2
—
—
—
0
0
11
22
5.37
4.11
2.0
1.5
—
—
—
0
0
9
14
6.83
4.06
1.8
1.9
—
—
—
0
0
49
291
2.12
3.88
5.5
3.4
0.45
0.33
e6/l
0.18
41
226
7
8
9.18
3.82
1.1
1.5
—
—
—
0
0
6
5
12.50
3.80
6.0
2.0
—
—
—
0
0
6
5
12.50
3.80
5.8
2.0
—
—
—
0
0
6
5
12.50
3.80
5.8
2.0
—
—
—
0
0
6
5
12.50
3.80
5.8
2.0
—
—
—
0
0
6
5
12.50
3.80
6.0
2.0
—
—
—
0
0
6
6
10.42
3.53
1.3
1.0
—
—
—
0
0
6
6
10.42
3.53
1.8
3.8
107.17
81.33
%
—
6
6
9
18
5.30
3.44
1.3
1.3
—
—
—
0
0
12
36
3.58
3.12
5.3
1.9
—
—
—
0
0
7
12
6.10
3.06
1.0
1.0
—
—
—
0
0
21
96
2.43
3.04
6.5
3.3
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
5
5
10.34
3.00
1.6
1.2
—
—
—
0
0
54
361
1.87
2.90
5.1
3.8
27.51
27.97
ng/l
0.03
44
243
54
362
1.87
2.87
2.4
1.9
79.88
95.69
pmol/l
2.60
37
193
31
172
2.07
2.84
4.3
3.2
39.96
134.98
ng/l
1.28
26
125
13
48
2.91
2.81
3.1
1.6
—
—
—
0
0
12
41
3.13
2.71
9.7
3.3
25.13
24.76
mmol/l
0.14
12
41
67
488
1.80
2.67
5.7
3.6
0.00
0.01
estimate
0.50
23
105
67
488
1.80
2.67
7.5
5.0
0.00
0.00
estimate
-0.00
22
98
6
11
5.67
2.57
1.0
1.1
—
—
—
0
0
6
11
5.67
2.57
2.7
1.3
—
—
—
0
0
6
11
5.67
2.57
2.7
1.3
—
—
—
0
0
6
11
5.67
2.57
2.7
1.3
—
—
—
0
0
6
11
5.67
2.57
1.2
1.9
—
—
—
0
0
5
7
7.38
2.57
1.6
1.0
—
—
—
0
0
67
493
1.77
2.54
5.7
3.6
0.00
0.00
estimate
-0.00
22
95
42
272
1.82
2.42
1.9
1.7
1.97
1.35
mmol/l
2.77
35
233
9
28
3.38
2.36
3.1
4.8
22.72
24.29
mmol/l
—
9
28
41
266
1.81
2.34
6.2
3.9
0.00
0.01
estimate
0.50
21
98
5
9
5.73
2.23
1.0
1.0
—
—
—
0
0
5
9
5.73
2.23
1.0
1.0
—
—
—
0
0
5
9
5.73
2.23
1.6
1.4
—
—
—
0
0
5
9
5.73
2.23
1.0
1.0
—
—
—
0
0
5
9
5.73
2.23
1.0
1.0
—
—
—
0
0
5
9
5.73
2.23
1.0
1.0
—
—
—
0
0
5
9
5.73
2.23
5.2
4.8
—
—
—
0
0
14
62
2.42
2.17
3.1
2.9
88.43
105.11
ng/l
0.16
14
56
10
38
2.77
2.06
1.6
1.2
—
—
—
0
0
7
21
3.47
1.99
2.9
1.2
—
—
—
0
0
11
45
2.58
1.99
2.5
1.2
—
—
—
0
0
5
11
4.68
1.96
3.0
1.3
—
—
—
0
0
5
11
4.68
1.96
3.0
1.3
—
—
—
0
0
5
11
4.68
1.96
3.0
1.3
—
—
—
0
0
30
188
1.78
1.89
1.4
1.2
48.33
24.94
iu/ml
0.48
12
61
6
19
3.26
1.68
2.0
1.6
—
—
—
0
0
6
19
3.26
1.68
2.0
1.6
—
—
—
0
0
51
385
1.55
1.54
6.0
3.7
—
—
—
0
0
5
15
3.43
1.54
5.0
3.5
—
—
—
0
0
25
160
1.70
1.46
5.2
3.3
1.09
1.99
e6/l
0.62
16
97
105
939
1.74
1.45
5.1
4.3
1.89
1.90
mu/l
0.02
105
855
5
16
3.21
1.45
1.0
1.1
—
—
—
0
0
114
1045
2.03
1.44
50.9
12.7
29.99
23.08
mg/l
1.54
103
791
9
41
2.29
1.40
20.0
3.8
39.70
53.92
%
—
9
41
10
47
2.23
1.38
29.9
2.7
0.60
0.73
%
—
10
47
8
34
2.44
1.32
3.4
1.7
—
—
—
0
0
13
71
1.93
1.25
1.6
2.6
59.50
68.56
ml/min/173m2
—
6
32
5
19
2.70
1.22
1.0
1.0
—
—
—
0
0
25
170
1.59
1.16
4.8
3.1
1.22
0.86
e6/l
0.31
16
107
17
106
1.70
1.09
2.4
5.3
27.36
48.22
ug/l
0.18
11
88
113
1052
1.77
1.07
46.2
15.0
139.19
139.78
mmol/l
2.02
113
1029
37
284
1.43
0.98
6.6
3.7
15.10
7.71
mg/mmol
0.47
30
176
24
170
1.51
0.94
1.3
1.2
62.93
5.02
u/ml
—
6
64
113
1059
1.70
0.94
49.0
15.1
3.99
3.98
mmol/l
0.14
113
1030
10
59
1.76
0.78
3.8
3.6
0.26
0.12
e6/l
—
10
59
15
100
1.57
0.77
1.8
2.4
29.20
29.63
u/l
0.04
15
84
10
62
1.67
0.67
7.9
13.9
22.86
25.15
mmol/l
—
10
57
6
102
0.57
0.65
1.5
1.6
—
—
—
0
0
103
965
1.38
0.65
5.7
4.3
5.92
5.92
mmol/l
0.00
95
885
29
234
1.31
0.56
1.4
1.7
—
—
—
0
0
99
936
1.28
0.47
39.5
11.9
82.62
84.56
ml/min/173m2
0.36
91
755
18
139
1.34
0.47
1.4
2.2
1.62
1.46
%
0.40
13
127
115
1110
1.45
0.46
35.5
9.6
39.41
27.25
u/l
1.92
115
1076
11
146
0.73
0.38
3.7
2.0
—
—
—
0
0
23
273
0.81
0.36
3.3
4.0
22.16
23.20
%
—
10
108
89
931
0.85
0.31
5.9
5.4
39.33
39.78
mmol/mol
0.14
81
864
14
112
1.28
0.30
4.3
4.5
25.64
32.17
%
1.58
14
71
10
78
1.31
0.25
2.1
2.5
6.49
5.17
ug/l
—
10
72
5
37
1.37
0.24
2.4
1.6
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
182.08
—
0
11
0
10
0.00
0.21
0.0
1.8
—
—
—
0
0
0
13
0.00
0.21
0.0
1.1
—
—
—
0
0
12
99
1.23
0.20
14.0
7.9
—
—
—
0
0
99
1016
0.88
0.18
5.2
4.8
2.49
2.74
mmol/l
1.46
92
940
11
131
0.82
0.18
3.7
1.8
—
—
—
0
0
5
65
0.76
0.17
1.6
2.1
—
—
—
0
0
117
1178
0.89
0.16
66.4
19.0
123.74
137.74
g/l
9.65
117
1165
12
102
1.20
0.16
3.3
2.2
9.17
15.43
nmol/l
2.31
12
96
30
278
1.10
0.13
1.3
1.5
0.59
1.27
u/ml
—
7
64
98
994
0.93
0.07
5.1
4.3
1.23
1.43
mmol/l
4.01
92
918
75
736
1.05
0.05
3.6
3.2
—
—
—
0
0
99
999
0.96
0.03
5.1
4.4
4.32
4.61
mmol/l
1.78
93
932
12
118
1.02
0.00
1.8
1.3
—
—
—
0
0
0
8
0.00
0.00
0.0
2.4
—
—
—
0
0
0
8
0.00
0.00
0.0
2.0
—
17.65
—
0
8
0
8
0.00
0.00
0.0
2.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
6.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
6.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
5.3
—
61.57
—
0
7
0
7
0.00
-0.00
0.0
1.6
—
—
—
0
0
5
58
0.86
-0.00
1.0
1.3
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint D3_OTHDISLYMPHORETANDRETICULOHIST and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| D3_OTHDISLYMPHORETANDRETICULOHIST | 4.294 [2.6, 7.1] | < 0.001 |
| Birth year | 0.998 [0.99, 1.01] | 0.683 |
During the follow-up period (1.1.1998 — 31.12.2019), 66 out of 345 females with D3_OTHDISLYMPHORETANDRETICULOHIST died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| D3_OTHDISLYMPHORETANDRETICULOHIST | 3.517 [2.18, 5.68] | < 0.001 |
| Birth year | 0.99 [0.98, 1.0] | 0.029 |
During the follow-up period (1.1.1998 — 31.12.2019), 65 out of 367 males with D3_OTHDISLYMPHORETANDRETICULOHIST died.
Mortality risk
Mortality risk for people of age
years, who have D3_OTHDISLYMPHORETANDRETICULOHIST.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.342% | 0.823% |
| 5 | 2.472% | 4.244% |
| 10 | 5.771% | 10.339% |
| 15 | 11.403% | 19.136% |
| 20 | 20.89% | 30.915% |
Relationships between endpoints
↥Index endpoint: D3_OTHDISLYMPHORETANDRETICULOHIST – Other specified diseases with participation of lymphoreticular and reticulohistiocytic tissue
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data